CYNATA THERAPEUTICS LIMITED - Announcements

Market Cap $42.21M Add to my watchlist

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) is stepping up its trial activities in Australia’s nearest Asian neighbour, Indonesia. Recce’s flagship anti-infective, R327, can be applied as a gel – and this gel-based version of the drug has been of specific interest...

Announcements

Filter Results

All Price Sensitive Only

CYP	Cynata Announces Positive Results from GvHD Trial Follow-up	PRICE SENSITIVE	30/07/20	215.76KB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	28/07/20	330.6KB	Share
CYP	Notification of Expiry of Unlisted Options		20/07/20	181.75KB	Share
CYP	Securities Dealing Policy		01/07/20	173.73KB	Share
CYP	Final Director's Interest Notice		01/07/20	26.83KB	Share
CYP	Appendix 3Y-Dr Geoff Brooke		24/06/20	25.66KB	Share
CYP	Ethics Approval & Expedited Pathway for Phase 3 OA Trial	PRICE SENSITIVE	18/06/20	211.79KB	Share
CYP	Appendix 3X-Darryl Maher		16/06/20	29.64KB	Share
CYP	Appendix 3Y-Ross Macdonald		16/06/20	25.53KB	Share
CYP	Appendix 3Y-Stewart Washer		16/06/20	25.2KB	Share
CYP	Dr Darryl Maher joins Cynata Board		16/06/20	207.69KB	Share
CYP	Block Trade Proceeds to Reduce Director Loans	PRICE SENSITIVE	16/06/20	202.1KB	Share
CYP	Appendix 2A		10/06/20	165.93KB	Share
CYP	Investor Presentation		10/06/20	1.71MB	Share
CYP	Appendix 2A		02/06/20	166.6KB	Share
CYP	Cynata Successfully Completes Share Purchase Plan	PRICE SENSITIVE	27/05/20	174.02KB	Share
CYP	Ethics Approval to Commence Clinical Trial in COVID-19	PRICE SENSITIVE	08/05/20	210.99KB	Share
CYP	Cleansing Notice		01/05/20	124.37KB	Share
CYP	Appendix 2A		01/05/20	168.11KB	Share
CYP	Share Purchase Plan Booklet	PRICE SENSITIVE	30/04/20	169.42KB	Share
CYP	Cleansing Notice		24/04/20	123.75KB	Share
CYP	Appendix 2A		24/04/20	168.82KB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	24/04/20	293.28KB	Share
CYP	Cynata announces $5.55m capital raising	PRICE SENSITIVE	22/04/20	212.56KB	Share
CYP	Proposed Issue of Securities		22/04/20	415.3KB	Share
CYP	Trading Halt	PRICE SENSITIVE	20/04/20	242.54KB	Share
CYP	Cynata MSCs beneficial in preclinical ARDS study	PRICE SENSITIVE	17/04/20	241.24KB	Share
CYP	Cynata provides guidance on planned clinical trials	PRICE SENSITIVE	01/04/20	195.85KB	Share
CYP	Market Update & Additional A$618k R&D Tax Refund	PRICE SENSITIVE	11/03/20	201.52KB	Share
CYP	Cynata Receives Japan Patent Notice of Allowance		10/03/20	192.12KB	Share
CYP	Canadian Patent Issued for CYP Unique Stem Cell Technology		03/03/20	182.01KB	Share
CYP	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	20/02/20	680.83KB	Share
CYP	Notice of Allowance from Israel Patent Office	PRICE SENSITIVE	06/02/20	184.85KB	Share
CYP	Cynata Investor Presentation		31/01/20	1.65MB	Share
CYP	December 2019 Quarterly Report	PRICE SENSITIVE	30/01/20	394.94KB	Share
CYP	Cynata Receives UK Regulatory Approval for CLI Trial	PRICE SENSITIVE	14/01/20	197.59KB	Share
CYP	Cynata Receives $1.892m R&D Tax Incentive Refund	PRICE SENSITIVE	07/01/20	159.51KB	Share
CYP	Appendix 3Y-Dr Paul Wotton		16/12/19	25.68KB	Share
CYP	Corporate Presentation in Relation to Sepsis		09/12/19	1.48MB	Share
CYP	Cymerus MSCs Effective in Preclinical Model of Sepsis	PRICE SENSITIVE	05/12/19	171.52KB	Share
CYP	Results of Annual General Meeting		27/11/19	188.16KB	Share
CYP	Cynata Annual General Meeting Presentation		27/11/19	1.78MB	Share
CYP	Chairman's 2019 AGM Address		27/11/19	145.57KB	Share
CYP	CYP Files Application to Commence Phase 2 CLI Clinical Trial	PRICE SENSITIVE	25/11/19	195.33KB	Share
CYP	Appendix 3Y-Dr Paul Wotton		18/11/19	26.03KB	Share
CYP	Notification of Expiry of Unlisted Options		18/11/19	156.49KB	Share
CYP	Appendix 3Y-Mr Peter Webse		11/11/19	26.72KB	Share
CYP	Appendix 3Y-Dr Ross Macdonald		11/11/19	26.5KB	Share
CYP	Appendix 3Y-Dr Paul Wotton		11/11/19	26.75KB	Share
CYP	Cleansing Notice		11/11/19	104.21KB	Share
CYP	Appendix 3B-Exercise of Options		11/11/19	187.34KB	Share
CYP	Cynata Corporate Presentation		30/10/19	1.63MB	Share
CYP	Cynata Awarded Grant for Coronary Artery Disease Study	PRICE SENSITIVE	28/10/19	186.55KB	Share
CYP	Notice of Allowance from CIPO for Patent Application	PRICE SENSITIVE	25/10/19	185.68KB	Share
CYP	Annual Report to shareholders		24/10/19	1.25MB	Share
CYP	Notice of Annual General Meeting/Proxy Form		24/10/19	1.04MB	Share
CYP	September 2019 Quarterly Report	PRICE SENSITIVE	24/10/19	345.42KB	Share
CYP	Cynata & Sumitomo Withdraw from Acquisition Discussions	PRICE SENSITIVE	17/10/19	177.78KB	Share
CYP	Receipt of notice under section 249N of the Corporations Act		14/10/19	2.49MB	Share
CYP	CYP Advances Towards Osteoarthritis Phase 2 Clinical Trial	PRICE SENSITIVE	03/10/19	210.02KB	Share
CYP	Notification of 2019 Annual General Meeting Date		27/09/19	160.59KB	Share
CYP	Cynata Receives US$3 million Fujifilm License Fee	PRICE SENSITIVE	26/09/19	162.19KB	Share
CYP	Cleansing Notice		18/09/19	102.27KB	Share
CYP	Appendix 3B-Exercise of Options		18/09/19	187.5KB	Share
CYP	Fujifilm Exercises License Option in GvHD	PRICE SENSITIVE	17/09/19	209.92KB	Share
CYP	Trading Halt	PRICE SENSITIVE	13/09/19	186.48KB	Share
CYP	Expiry of Voluntary Escrow Arrangement		09/09/19	184.51KB	Share
CYP	Cynata transplant rejection study accepted for publication		04/09/19	202.21KB	Share
CYP	Cleansing Notice		03/09/19	102.5KB	Share
CYP	Appendix 3B-Exercise of Options		03/09/19	187.38KB	Share
CYP	Cleansing Notice		27/08/19	102.25KB	Share
CYP	Appendix 3B-Exercise of Options		27/08/19	187.21KB	Share
CYP	Appendix 4G		23/08/19	221.07KB	Share
CYP	Appendix 4E & Annual Report	PRICE SENSITIVE	23/08/19	1.26MB	Share
CYP	Cleansing Notice		15/08/19	102.25KB	Share
CYP	Appendix 3B-Exercise of Options		15/08/19	188.97KB	Share
CYP	Update on Discussions with Sumitomo and Fujifilm	PRICE SENSITIVE	15/08/19	182.65KB	Share
CYP	Cleansing Notice		02/08/19	102.54KB	Share
CYP	Appendix 3B-Exercise of Options		02/08/19	190.6KB	Share
CYP	Response to ASX Aware Query	PRICE SENSITIVE	24/07/19	785.23KB	Share
CYP	Response to ASX Price and Volume Query	PRICE SENSITIVE	19/07/19	537.26KB	Share
CYP	Cynata confirms receipt of indicative non-binding proposal	PRICE SENSITIVE	19/07/19	184.58KB	Share
CYP	Trading Halt	PRICE SENSITIVE	17/07/19	214.44KB	Share
CYP	June 2019 Quarterly Report	PRICE SENSITIVE	04/07/19	393.87KB	Share
CYP	Cynata's Cymerus Technology Featured in ISCT Presentations		30/05/19	217.24KB	Share
CYP	Appendix 3Z-Dr John Chiplin		20/05/19	27.07KB	Share
CYP	Appendix 3Y-Dr Geoff Brooke		20/05/19	29.65KB	Share
CYP	Appendix 3B		20/05/19	190.39KB	Share
CYP	Cynata Strengthens Board & Executive Management Team	PRICE SENSITIVE	20/05/19	205.83KB	Share
CYP	Appendix 3Y-Dr John Chiplin		07/05/19	24.83KB	Share
CYP	Cleansing Notice		07/05/19	102.05KB	Share
CYP	Appendix 3B - Exercise of Options		07/05/19	188.67KB	Share
CYP	CYP Progresses Start-Up Activities for Clinical Trial in CLI		06/05/19	175.91KB	Share
CYP	March 2019 Quarterly Report	PRICE SENSITIVE	26/04/19	384.45KB	Share
CYP	European Patent Isued to Cynata Therapeutics		04/04/19	201.83KB	Share
CYP	Extension of FUJIFILM Licence Option in GvHD		21/03/19	194.68KB	Share
CYP	Cleansing Notice		21/03/19	102.42KB	Share
CYP	Cynata Extends FUJIFILM Licence Option in GvHD	PRICE SENSITIVE	21/03/19	196.96KB	Share
CYP	Appendix 3B-Exercise of Options		20/03/19	189.25KB	Share
CYP	Trading Halt	PRICE SENSITIVE	19/03/19	329.31KB	Share

CYP Cynata Announces Positive Results from GvHD Trial Follow-up
30/07/20	PRICE SENSITIVE	215.76KB	Share
CYP Quarterly Activity Report & Appendix 4C
28/07/20	PRICE SENSITIVE	330.6KB	Share
CYP Notification of Expiry of Unlisted Options
20/07/20		181.75KB	Share
CYP Securities Dealing Policy
01/07/20		173.73KB	Share
CYP Final Director's Interest Notice
01/07/20		26.83KB	Share
CYP Appendix 3Y-Dr Geoff Brooke
24/06/20		25.66KB	Share
CYP Ethics Approval & Expedited Pathway for Phase 3 OA Trial
18/06/20	PRICE SENSITIVE	211.79KB	Share
CYP Appendix 3X-Darryl Maher
16/06/20		29.64KB	Share
CYP Appendix 3Y-Ross Macdonald
16/06/20		25.53KB	Share
CYP Appendix 3Y-Stewart Washer
16/06/20		25.2KB	Share
CYP Dr Darryl Maher joins Cynata Board
16/06/20		207.69KB	Share
CYP Block Trade Proceeds to Reduce Director Loans
16/06/20	PRICE SENSITIVE	202.1KB	Share
CYP Appendix 2A
10/06/20		165.93KB	Share
CYP Investor Presentation
10/06/20		1.71MB	Share
CYP Appendix 2A
02/06/20		166.6KB	Share
CYP Cynata Successfully Completes Share Purchase Plan
27/05/20	PRICE SENSITIVE	174.02KB	Share
CYP Ethics Approval to Commence Clinical Trial in COVID-19
08/05/20	PRICE SENSITIVE	210.99KB	Share
CYP Cleansing Notice
01/05/20		124.37KB	Share
CYP Appendix 2A
01/05/20		168.11KB	Share
CYP Share Purchase Plan Booklet
30/04/20	PRICE SENSITIVE	169.42KB	Share
CYP Cleansing Notice
24/04/20		123.75KB	Share
CYP Appendix 2A
24/04/20		168.82KB	Share
CYP Quarterly Activity Report & Appendix 4C
24/04/20	PRICE SENSITIVE	293.28KB	Share
CYP Cynata announces $5.55m capital raising
22/04/20	PRICE SENSITIVE	212.56KB	Share
CYP Proposed Issue of Securities
22/04/20		415.3KB	Share
CYP Trading Halt
20/04/20	PRICE SENSITIVE	242.54KB	Share
CYP Cynata MSCs beneficial in preclinical ARDS study
17/04/20	PRICE SENSITIVE	241.24KB	Share
CYP Cynata provides guidance on planned clinical trials
01/04/20	PRICE SENSITIVE	195.85KB	Share
CYP Market Update & Additional A$618k R&D Tax Refund
11/03/20	PRICE SENSITIVE	201.52KB	Share
CYP Cynata Receives Japan Patent Notice of Allowance
10/03/20		192.12KB	Share
CYP Canadian Patent Issued for CYP Unique Stem Cell Technology
03/03/20		182.01KB	Share
CYP Appendix 4D & Half-Year Financial Statements
20/02/20	PRICE SENSITIVE	680.83KB	Share
CYP Notice of Allowance from Israel Patent Office
06/02/20	PRICE SENSITIVE	184.85KB	Share
CYP Cynata Investor Presentation
31/01/20		1.65MB	Share
CYP December 2019 Quarterly Report
30/01/20	PRICE SENSITIVE	394.94KB	Share
CYP Cynata Receives UK Regulatory Approval for CLI Trial
14/01/20	PRICE SENSITIVE	197.59KB	Share
CYP Cynata Receives $1.892m R&D Tax Incentive Refund
07/01/20	PRICE SENSITIVE	159.51KB	Share
CYP Appendix 3Y-Dr Paul Wotton
16/12/19		25.68KB	Share
CYP Corporate Presentation in Relation to Sepsis
09/12/19		1.48MB	Share
CYP Cymerus MSCs Effective in Preclinical Model of Sepsis
05/12/19	PRICE SENSITIVE	171.52KB	Share
CYP Results of Annual General Meeting
27/11/19		188.16KB	Share
CYP Cynata Annual General Meeting Presentation
27/11/19		1.78MB	Share
CYP Chairman's 2019 AGM Address
27/11/19		145.57KB	Share
CYP CYP Files Application to Commence Phase 2 CLI Clinical Trial
25/11/19	PRICE SENSITIVE	195.33KB	Share
CYP Appendix 3Y-Dr Paul Wotton
18/11/19		26.03KB	Share
CYP Notification of Expiry of Unlisted Options
18/11/19		156.49KB	Share
CYP Appendix 3Y-Mr Peter Webse
11/11/19		26.72KB	Share
CYP Appendix 3Y-Dr Ross Macdonald
11/11/19		26.5KB	Share
CYP Appendix 3Y-Dr Paul Wotton
11/11/19		26.75KB	Share
CYP Cleansing Notice
11/11/19		104.21KB	Share
CYP Appendix 3B-Exercise of Options
11/11/19		187.34KB	Share
CYP Cynata Corporate Presentation
30/10/19		1.63MB	Share
CYP Cynata Awarded Grant for Coronary Artery Disease Study
28/10/19	PRICE SENSITIVE	186.55KB	Share
CYP Notice of Allowance from CIPO for Patent Application
25/10/19	PRICE SENSITIVE	185.68KB	Share
CYP Annual Report to shareholders
24/10/19		1.25MB	Share
CYP Notice of Annual General Meeting/Proxy Form
24/10/19		1.04MB	Share
CYP September 2019 Quarterly Report
24/10/19	PRICE SENSITIVE	345.42KB	Share
CYP Cynata & Sumitomo Withdraw from Acquisition Discussions
17/10/19	PRICE SENSITIVE	177.78KB	Share
CYP Receipt of notice under section 249N of the Corporations Act
14/10/19		2.49MB	Share
CYP CYP Advances Towards Osteoarthritis Phase 2 Clinical Trial
03/10/19	PRICE SENSITIVE	210.02KB	Share
CYP Notification of 2019 Annual General Meeting Date
27/09/19		160.59KB	Share
CYP Cynata Receives US$3 million Fujifilm License Fee
26/09/19	PRICE SENSITIVE	162.19KB	Share
CYP Cleansing Notice
18/09/19		102.27KB	Share
CYP Appendix 3B-Exercise of Options
18/09/19		187.5KB	Share
CYP Fujifilm Exercises License Option in GvHD
17/09/19	PRICE SENSITIVE	209.92KB	Share
CYP Trading Halt
13/09/19	PRICE SENSITIVE	186.48KB	Share
CYP Expiry of Voluntary Escrow Arrangement
09/09/19		184.51KB	Share
CYP Cynata transplant rejection study accepted for publication
04/09/19		202.21KB	Share
CYP Cleansing Notice
03/09/19		102.5KB	Share
CYP Appendix 3B-Exercise of Options
03/09/19		187.38KB	Share
CYP Cleansing Notice
27/08/19		102.25KB	Share
CYP Appendix 3B-Exercise of Options
27/08/19		187.21KB	Share
CYP Appendix 4G
23/08/19		221.07KB	Share
CYP Appendix 4E & Annual Report
23/08/19	PRICE SENSITIVE	1.26MB	Share
CYP Cleansing Notice
15/08/19		102.25KB	Share
CYP Appendix 3B-Exercise of Options
15/08/19		188.97KB	Share
CYP Update on Discussions with Sumitomo and Fujifilm
15/08/19	PRICE SENSITIVE	182.65KB	Share
CYP Cleansing Notice
02/08/19		102.54KB	Share
CYP Appendix 3B-Exercise of Options
02/08/19		190.6KB	Share
CYP Response to ASX Aware Query
24/07/19	PRICE SENSITIVE	785.23KB	Share
CYP Response to ASX Price and Volume Query
19/07/19	PRICE SENSITIVE	537.26KB	Share
CYP Cynata confirms receipt of indicative non-binding proposal
19/07/19	PRICE SENSITIVE	184.58KB	Share
CYP Trading Halt
17/07/19	PRICE SENSITIVE	214.44KB	Share
CYP June 2019 Quarterly Report
04/07/19	PRICE SENSITIVE	393.87KB	Share
CYP Cynata's Cymerus Technology Featured in ISCT Presentations
30/05/19		217.24KB	Share
CYP Appendix 3Z-Dr John Chiplin
20/05/19		27.07KB	Share
CYP Appendix 3Y-Dr Geoff Brooke
20/05/19		29.65KB	Share
CYP Appendix 3B
20/05/19		190.39KB	Share
CYP Cynata Strengthens Board & Executive Management Team
20/05/19	PRICE SENSITIVE	205.83KB	Share
CYP Appendix 3Y-Dr John Chiplin
07/05/19		24.83KB	Share
CYP Cleansing Notice
07/05/19		102.05KB	Share
CYP Appendix 3B - Exercise of Options
07/05/19		188.67KB	Share
CYP CYP Progresses Start-Up Activities for Clinical Trial in CLI
06/05/19		175.91KB	Share
CYP March 2019 Quarterly Report
26/04/19	PRICE SENSITIVE	384.45KB	Share
CYP European Patent Isued to Cynata Therapeutics
04/04/19		201.83KB	Share
CYP Extension of FUJIFILM Licence Option in GvHD
21/03/19		194.68KB	Share
CYP Cleansing Notice
21/03/19		102.42KB	Share
CYP Cynata Extends FUJIFILM Licence Option in GvHD
21/03/19	PRICE SENSITIVE	196.96KB	Share
CYP Appendix 3B-Exercise of Options
20/03/19		189.25KB	Share
CYP Trading Halt
19/03/19	PRICE SENSITIVE	329.31KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last 23.5¢		Change 0.000(0.00%)		Mkt cap ! $42.21M

Open	High	Low	Value	Volume
22.0¢	23.5¢	22.0¢	$20.38K	90.67K

Buyers (Bids)

No.	Vol.	Price($)
1	86380	21.0¢

Sellers (Offers)

Price($)	Vol.	No.
23.5¢	12372	2

View Market Depth

No.	Vol.	Price($)
1	86380	0.210
4	165257	0.200
2	13135	0.195
1	30000	0.190
3	102017	0.185

Price($)	Vol.	No.
0.235	12372	2
0.240	91350	1
0.245	10000	1
0.250	42019	2
0.275	21895	1

Last trade - 16.10pm 09/05/2024 (20 minute delay)


Last 23.0¢		Change 0.000 ( 2.22 %)
Open	High	Low	Volume
23.0¢	23.0¢	23.0¢	10474
Last updated 11.40am 09/05/2024 ?

CYP (ASX) Chart

CYNATA THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories